McDermott advises Ren Life Sciences on majority stake acquisition in 53Biologics | McDermott Skip to main content

McDermott advises Ren Life Sciences on majority stake acquisition in 53Biologics

Overview


International law firm McDermott Will & Schulte advised Ren Life Sciences, a European life sciences investment firm, on its acquisition of a majority stake in 53Biologics, a Spanish-based contract development and manufacturing organization (CDMO) focused on production of biological drugs.

Ren Life Sciences is a specialised Life Sciences investor focused on supporting innovative European businesses scale while creating high-value scientific jobs across Europe

The transaction strengthens 53Biologics’ position as a leading player in Europe’s biomanufacturing infrastructure, enabling the company to drive key strategic initiatives across capability integration, capacity expansion, and geographic growth. As part of the deal, McDermott also advised on the parties’ bespoke go-forward equity arrangements.

The McDermott team was led by partner Fatema Orjela and included counsel Zoe Woodhouse and associate Raees Khan.

About Us


Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,700+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.